Trilogy Global Advisors LP decreased its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 8.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 384,127 shares of the biopharmaceutical company’s stock after selling 33,553 shares during the period. Trilogy Global Advisors LP’s holdings in Gilead Sciences were worth $32,043,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of GILD. Bank of Montreal Can bought a new position in shares of Gilead Sciences during the second quarter valued at about $427,750,000. Investec Asset Management LTD bought a new position in shares of Gilead Sciences during the first quarter valued at about $280,342,000. Parnassus Investments CA boosted its position in shares of Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock valued at $705,774,000 after buying an additional 2,640,284 shares in the last quarter. NN Investment Partners Holdings N.V. bought a new position in shares of Gilead Sciences during the first quarter valued at about $180,268,000. Finally, Beacon Investment Advisory Services Inc. boosted its position in shares of Gilead Sciences by 9,951.3% in the second quarter. Beacon Investment Advisory Services Inc. now owns 1,653,145 shares of the biopharmaceutical company’s stock valued at $1,379,000 after buying an additional 1,636,698 shares in the last quarter. 77.94% of the stock is owned by hedge funds and other institutional investors.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.67% during midday trading on Tuesday, reaching $77.51. 1,560,751 shares of the company were exchanged. Gilead Sciences Inc. has a 52 week low of $76.67 and a 52 week high of $111.11. The firm has a market capitalization of $102.29 billion, a P/E ratio of 6.80 and a beta of 1.10. The firm has a 50-day moving average of $79.35 and a 200 day moving average of $85.39.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The firm earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. During the same quarter in the prior year, the firm posted $3.15 earnings per share. Gilead Sciences’s quarterly revenue was down 5.7% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences Inc. will post $11.76 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were given a $0.47 dividend. The ex-dividend date was Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 2.41%. Gilead Sciences’s payout ratio is currently 16.56%.
Several brokerages recently issued reports on GILD. RBC Capital Markets reiterated a “buy” rating and set a $95.00 price target (down previously from $105.00) on shares of Gilead Sciences in a research report on Monday. Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Monday. Leerink Swann reiterated an “outperform” rating and set a $112.00 price target on shares of Gilead Sciences in a research report on Friday. Goldman Sachs Group Inc. restated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a report on Tuesday, September 27th. Finally, Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Monday, September 26th. Ten equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $104.63.
In other Gilead Sciences news, Director Kevin E. Lofton sold 3,500 shares of the company’s stock in a transaction dated Wednesday, August 24th. The shares were sold at an average price of $81.97, for a total value of $286,895.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the company’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total transaction of $409,200.00. Following the completion of the transaction, the executive vice president now directly owns 132,964 shares in the company, valued at approximately $10,881,773.76. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by company insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.